Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCaja Costarricense de Seguro Social

About this trial

The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:

What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?

What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?

Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.

Eligibility criteria

Qualifiers

Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria

Moderate-to-severe disease requiring systemic or advanced therapy

Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care

Evaluated in participating dermatology centers in Costa Rica

Disqualifiers

Lack of sufficient clinical data for severity or treatment assessment

Trial design

Treatments tested in this trial

  • Abrocitinib
  • Upadacitinib
  • Baricitinib
  • Dupilumab

Treatment groups

No treatment groups listed